tert.-Butyl-(3-thienyl)-sulfon | 19509-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: tert.-Butyl-(3-thienyl)-sulfon
• 英文别名: 3-(tert-Butylsulfonyl)thiophene；3-tert-butylsulfonylthiophene
• CAS: 19509-70-7
• 化学式: C₈H₁₂O₂S₂
• 分子量: 204.314
• InChiKey: TYDVZGWWUBQJBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  70.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Quinoxalinyl tripeptide hepatitis C virus inhibitors
  申请人：Gai Yonghua

  公开号：US20080032936A1

  公开（公告）日：2008-02-07

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I的化合物，或其药用可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，同时也可用作抗病毒药物。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投与含本发明化合物的药物组合物来治疗HCV感染的方法。
• ANTIVIRAL COMPOUNDS
  申请人：Casarez Anthony

  公开号：US20110135604A1

  公开（公告）日：2011-06-09

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  这项发明涉及抗病毒化合物、含有这些化合物的组合物和包括给予这些化合物的治疗方法，以及用于制备这些化合物的有用过程和中间体。
• MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080008681A1

  公开（公告）日：2008-01-10

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20090005387A1

  公开（公告）日：2009-01-01

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC
  申请人：Burns Barbier Lindsay

  公开号：US20110105484A1

  公开（公告）日：2011-05-05

  A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within.